PDCD1 and non-small cell lung carcinoma: In another publication, Rizvi et al. showed that high TMB assessed through targeted NGS (MSK-IMPACT) was associated with durable clinical benefit in a population of 240 NSCLC patients treated with anti-PD-1 or anti-PD-L1 agents and was independent from PD-L1 expression [35].